Brief: Northwest Biotherapeutics announces financings totaling $35 million
19/11/2014 20:20
Nov 19 (Reuters) - Northwest Biotherapeutics Inc NWBO.O : * Nw Bio announces financings totaling $35 million to expand and accelerate DCVAX-l and DCVAX-direct programs * Financings include $25 million investment by C.F. Woodford Equity Income Fund and $10 million mortgage on co's recently acquired UK facility * Funding will be used to further expand and accelerate the Phase III DCVAX-l clinical trial in GBM brain cancer * Source text for Eikon ID:nPn4dycwk * Further company coverage NWBO.O ((Bangalore Newsroom; +1 646 223 8780))
Recent news on Northwest Biotherapeutics
See all newsBrief: Northwest Biotherapeutics And The UK National Health Service Blood And Transplant Announce Collaboration To Support Dcvax®-L Production
Brief: Northwest Biotherapeutics Provides Update On Final Preparations For Marketing Authorization Application
Brief: Northwest Biotherapeutics Provides Update On Near Term Plans For Submission Of Marketing Authorization Application
Brief: Northwest Biotherapeutics And Advent Bioservices Announce Receipt Of License For Commercial Manufacturing At Sawston, U.K. Facility
Brief: Northwest Biotherapeutics Announces That It Has No Banking Relationship With SVB